title: Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-κB activity.
authors: Xiaohui
authors: X
authors: Hu
authors: Jingjing
authors: J
authors: Xu
authors: Aining
authors: A
authors: Sun
authors: Yaying
authors: Y
authors: Shen
authors: Guangsheng
authors: G
authors: He
authors: Feng
authors: F
authors: Guo
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D006801:Humans; D008297:Male; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism*; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D016328:NF-kappa B; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib